07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

Alere Inc, Qiagen deal

Qiagen purchased circulating tumor cell (CTC) detection technology and two diagnostics -- AdnaTest BreastCancer and AdnaTest Prostate Cancer -- from Alere’s AdnaGen GmbH subsidiary. AdnaTest BreastCancer is a breast cancer diagnostic that uses RT-PCR to...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

OncoVista deal

OncoVista will receive up to $65 million in cash and milestones as part of Alere Holdings Bermuda Ltd.'s acquisition of OncoVista's majority-held AdnaGen AG subsidiary. OncoVista has a 78% stake in the subsidiary. Alere will...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

OncoVista, TATAA Molecular Diagnostics deal

OncoVista's AdnaGen AG subsidiary granted TATAA exclusive rights to use its AdnaTest BreastCancer assay in the COHERTA project. The diagnostic uses RT-PCR to detect biomarkers in circulating tumor cells (CTC). The COHERTA study will evaluate...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Clinical News

AdnaTest BreastCancer: Post-marketing study data

Researchers at University Hospital Essen and University Hospital of Tuebingen reported that AdnaTest BreastCancer detected an EMT marker and ALDH1 in 62% and 69%, respectively, of 69 blood samples that were positive for CTCs from...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

AdnaTest BreastCancer update

This month, researchers will begin a laboratory study in samples from patients who have completed neoadjuvant and local therapy to compare AdnaTest BreastCancer diagnostic vs. CellSearch Circulating Tumor Cell Kit from Veridex LLC, a subsidiary...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Company News

AdnaGen, OncoVista deal

OncoVista increased its stake in AdnaGen to over 95% from 85% for an undisclosed amount. OncoVista said the acquisition will allow it to realize revenues from sales and to control the use of AdnaGen’s AdnaTest...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Company News

AdnaGen, OncoVista Inc. deal

AVUG increased its stake in AdnaGen to 85% from 51% for an undisclosed amount. AVUG acquired a majority stake in the company last year (see BioCentury, Feb. 27, 2006). AdnaGen markets the AdnaTest BreastCancer and...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Company News

AdnaGen, OncoVista Inc. deal

Cancer company OncoVista acquired a majority stake in AdnaGen for an undisclosed sum. AdnaGen markets the AdnaTest BreastCancer and AdnaTest ColonCancer blood tests, which measure circulating tumor cells. AdnaGen AG , Langenhagen, Germany   OncoVista...